1. Home
  2. KTTA vs QNCX Comparison

KTTA vs QNCX Comparison

Compare KTTA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.52

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$29.48

Market Cap

17.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KTTA
QNCX
Founded
2020
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
17.5M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
KTTA
QNCX
Price
$0.52
$29.48
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$3.00
N/A
AVG Volume (30 Days)
214.9K
14.1K
Earning Date
05-14-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
77.07
N/A
EPS
N/A
N/A
Revenue
$486,559.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3130.37
N/A
52 Week Low
$0.28
$0.08
52 Week High
$2.06
$35.41

Technical Indicators

Market Signals
Indicator
KTTA
QNCX
Relative Strength Index (RSI) 47.80 48.26
Support Level $0.48 $0.82
Resistance Level $0.52 $35.38
Average True Range (ATR) 0.04 2.14
MACD -0.01 -0.84
Stochastic Oscillator 34.21 34.79

Price Performance

Historical Comparison
KTTA
QNCX

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Share on Social Networks: